West Pharmaceutical Services (WST) Non-Current Assets (2009 - 2026)

West Pharmaceutical Services (WST) has reported Non-Current Assets for 18 consecutive years, with $2.3 billion the latest figure, recorded in Q2 2026.

• Quarterly Non-Current Assets changed 0.13% year-over-year to $2.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.1 billion (up 5.35% YoY) and the FY2025 annual result came in at $2.3 billion, up 8.86% from the prior year.
• Non-Current Assets declined to $2.3 billion in Q2 2026 per WST's latest filing, from $2.3 billion in the prior quarter.
• Over the last five years, Non-Current Assets for WST reached as high as $2.3 billion in Q4 2025 and fell as low as $1.6 billion in Q3 2022.
• A 5-year average of $2.0 billion and a median of $2.0 billion in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets advanced 19.19% — and 2026, when it declined 0.13%.
• Year by year, Non-Current Assets stood at $1.7 billion in 2022, then gained by 11.54% to $1.9 billion in 2023, then gained by 11.21% to $2.1 billion in 2024, then gained by 8.86% to $2.3 billion in 2025, then declined by 1.0% to $2.3 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $2.3 billion, $2.3 billion, and $2.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.